Digital Twins for Radiopharmaceutical Dosimetry: PBPK Modelling of [¹⁷⁷Lu]Lu-rhPSMA-10.1 in a Preclinical mCRPC Model.

ABSTRACT: Background/Objectives: Accurate absorbed dose estimation is essential for optimising targeted radionuclide therapy (TRT) in metastatic castration-resistant prostate cancer, where kidney toxicity is dose-limiting. [¹⁷⁷Lu]Lu-rhPSMA-10.1 is a novel PSMA-targeted radioligand with favourable tumour-to-kidney uptake ratios; however, inter-patient pharmacokinetic variability can lead to differences in organ and tumour absorbed doses under fixed-activity administration. Personalised dosimetry offers a means to address this variability. This work aims to create mouse PBPK model-based digital twins for [¹⁷⁷Lu]Lu-rhPSMA-10.1 to test the model's resistance to noise and evaluate its impact on accuracy and absorbed dose calculations. Methods: Five CB-17 SCID mice bear

SUBMITTER: Costa G 

PROVIDER: S-EPMC12730921 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature